In this exploratory pilot study of a subset of samples from the PIVENS trial, vitE responders displayed decreased levels of the metabolite sphingosine, which is hypothesized to reflect and correlate with decreased TNF-α activity, hereby supporting inflammation as a target in NASH resolution and a potential biomarker of disease severity [51]. The gene discussed is TNF; the disease is metabolic dysfunction-associated steatohepatitis.